so now the SP is back below where it was before the positive announcement of Ph II trials of 2591 for Pitt Hopkins Syndrome. The ASX has discounted any value to 2591 to treat another ailment. It's as if it's worth nothing. It doesn't make any sense at all. I'm still holding tightly, and if it wasn't for the fact I am greatly overweight in NEU already, I'd certainly be buying more right now.
- Forums
- ASX - By Stock
- NEU
- Share Price
Share Price, page-10325
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$17.03 |
Change
0.700(4.29%) |
Mkt cap ! $2.176B |
Open | High | Low | Value | Volume |
$16.49 | $17.21 | $16.44 | $11.40M | 677.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4624 | $17.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$17.05 | 20000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4624 | 17.020 |
4 | 2910 | 16.990 |
1 | 175 | 16.960 |
2 | 2090 | 16.950 |
1 | 118 | 16.940 |
Price($) | Vol. | No. |
---|---|---|
17.050 | 20000 | 1 |
17.160 | 759 | 2 |
17.200 | 2650 | 1 |
17.210 | 2175 | 2 |
17.220 | 1500 | 1 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online